News

06/11/2024

KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury

05/31/2024

Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst

05/30/2024

Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises

A tighter venture capital market has affected more than the funding biotechs receive. It’s also changed how early-stage companies structure CEO pay packages, according to Leslie Loveless, CEO and managing partner of Slone Partners, a life sciences and healthcare executive search firm. Because of how funding dipped, she told BioSpace, early-stage biotechs started tying CEO

05/29/2024

AMPEL BioSolutions Building Evidence for Prognostic Potential of Lupus Molecular Subtyping Test

AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations. In addition, the company has been conducting a study to see whether different lupus subtypes as defined by its test correlate with

05/29/2024

Virginia Medtech Company Is Awarded $13M Contract Continuation from the Navy

NIRSense Inc., headquartered in Richmond, Virginia, won an expansion to a competitively-awarded contract this month to build fieldable physiology monitors for the US Navy. NIRSense has been working with the Department of Defense since 2019 to build medical-grade physiology monitors to support US warfighter safety, performance, and medical care in training and operations. “NIRSense has

05/23/2024

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

Activation Capital announces the launch of Frontier BioHealth, an educational and support program designed to provide highly specialized training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies. The inaugural four-month program will be critical in bringing research-intense products and companies to market. It will broaden the

05/23/2024

Virginia Bio Announces Recipients of its 2024 Outstanding Contributions to Bioscience Award

Every two years, the Virginia Biotechnology Association recognizes individual Virginians for their significant contributions to bioscience and the Virginia biotechnology ecosystem.  On May 17, Jeff Conroy, former CEO of Embody, Inc., and Jim Powers, former CEO of HemoShear were presented with the Outstanding Contributions to Bioscience Award at Virginia Bio’s THRiVE 2024 statewide conference in

05/23/2024

SRI earns FDA Orphan Drug Designation for pancreatic cancer

SRI’s Targeted Antigen Loaded Liposomes (TALL) — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation (ODD) for pancreatic ductal adenocarcinoma (PDAC) by the U.S. Federal Drug Administration (FDA). As a result, SRI’s future strategic partners can gain tax credits for qualified clinical trials and potentially receive market exclusivity

05/20/2024

Governor Youngkin Announces New VIPC-Led Initiative that Catalyzes and Attracts Investment into Virginia-based, Innovation-driven Startups and Entrepreneurs

Governor Glenn Youngkin announced a new initiative led by Virginia Innovation Partnership Corporation (VIPC) that expands investment and growth opportunities for Virginia-based, innovation-driven startups and entrepreneurial ecosystems throughout the Commonwealth. Leveraging previous Virginia-awarded federal funding from the U.S. Department of Treasury, under its SSBCI Equity/Venture Capital Program, VIPC’s Virginia Invests launches new investment partnerships with an

05/12/2024

Nanochon closes $4M Series Seed Prime

Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to

05/09/2024

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction

05/08/2024

TechNite 2024 Celebrates the Elements of Tech

The Roanoke-Blacksburg Technology Council’s TechNite 2024 presented by Woods Rogers Vandeventer Black, recognized all the elements that make the Roanoke-Blacksburg innovation ecosystem so dynamic. TechNite 2024 was held Wednesday, May, 8 at the iconic Hotel Roanoke & Conference Center. RBTC’s annual celebration is highly anticipated within the regional technology community, and hundreds of local and

05/08/2024

Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy study

CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to move forward on an investigational cancer immunotherapy study for its drug Multikine. The project will study the drug’s effectiveness in newly diagnosed advanced primary head and neck cancer patients with no lymph node

05/06/2024

Phlow Corp. Appoints General Gustave F. Perna to the Phlow Business Advisory Board

Phlow Corp., a U.S.-based certified B Corporation leveraging advanced development and manufacturing processes to re-imagine the domestic production of pharmaceutical products critical to U.S. healthcare, announced today that it has appointed General Gustave F. Perna to the Phlow Business Advisory Board (PBAB). As America’s modern medicine manufacturer, Phlow works closely with its business advisory board,

05/02/2024

Caretaker Medical Unveils VitalStream Roadmap for Streamlined Cardiogenic Shock Monitoring at SCAI 2024

Caretaker Medical, a leading innovator in advanced hemodynamic monitoring solutions, today announced the launch of its VitalStream® Cardiogenic Shock Continuous Monitoring Roadmap at the Society for Cardiovascular Angiography and Interventions (SCAI) 2024 meeting. This roadmap aligns with the National Cardiogenic Shock Initiative[i] criteria and timelines, empowering clinicians with a streamlined approach to early identification, and

04/24/2024

VIPC Names Joe Benevento as President & CEO

The Board of Directors of the Virginia Innovation Partnership Corporation (VIPC) has announced that it has unanimously selected Joe Benevento as President and CEO of VIPC. Benevento has led VIPC as Interim President and CEO since September 2023 and previously served as Deputy Secretary of Commerce and Trade for the Commonwealth of Virginia since 2022.

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them

04/10/2024

Phlow kicks off drug ingredient production in Petersburg

A local pharma company and player in a regional effort to build a pharmaceutical hub in Central Virginia has started manufacturing operations. Richmond-based Phlow Corp. recently began manufacturing ingredients used in medicines at a facility at 2818 N. Normandy Drive in Petersburg, according to Robby Demeria, the company’s chief corporate affairs officer. The 19,200-square-foot facility

04/03/2024

TearSolutions, Inc. Appoints Dr. Louis M Alpern to its Board of Directors

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Louis M Alpern, MD, MPH, FACS, FICS has been appointed to the Company’s Board of Directors. “Dr. Alpern brings extensive real-world clinical experience treating patients with ocular

04/01/2024

RIVANNA® Welcomes Craig Loomis to Drive Product Excellence

RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Craig Loomis will play a vital role in advancing RIVANNA’s new product commercialization strategies. Before joining RIVANNA, Mr. Loomis held progressively responsible

03/28/2024

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure